Wave Life Sciences Ltd
$ 7.62
6.72%
04 Dec - close price
- Market Cap 1,273,925,000 USD
- Current Price $ 7.62
- High / Low $ 7.68 / 7.12
- Stock P/E N/A
- Book Value 0.78
- EPS -0.65
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.86 %
- 52 Week High 15.72
- 52 Week Low 5.28
About
Wave Life Sciences Ltd. is a pioneering clinical-stage biotechnology firm based in Singapore, dedicated to developing cutting-edge oligonucleotide therapeutics for severe genetic disorders. Leveraging its proprietary PRISM platform, the company creates stereopure oligonucleotides that significantly enhance the specificity and efficacy of genetic interventions. With a strong pipeline of innovative therapies aimed at addressing critical unmet medical needs, Wave Life Sciences is positioned as a transformative leader in genetic medicine, striving to improve patient outcomes around the world.
Analyst Target Price
$19.80
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-07-30 | 2025-05-07 | 2025-03-04 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-06 | 2023-11-09 | 2023-08-03 | 2023-05-03 | 2023-03-22 |
| Reported EPS | -0.32 | -0.31 | -0.29 | 0.17 | -0.466 | -0.25 | -0.24 | -0.15 | 0.07 | -0.2 | -0.27 | -0.47 |
| Estimated EPS | -0.2547 | -0.27 | -0.2556 | -0.17 | -0.28 | -0.21 | -0.21 | -0.23 | -0.18 | -0.33 | -0.04 | -0.41 |
| Surprise | -0.0653 | -0.04 | -0.0344 | 0.34 | -0.186 | -0.04 | -0.03 | 0.08 | 0.25 | 0.13 | -0.23 | -0.06 |
| Surprise Percentage | -25.638% | -14.8148% | -13.4585% | 200% | -66.4286% | -19.0476% | -14.2857% | 34.7826% | 138.8889% | 39.3939% | -575% | -14.6341% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: WVE
2025-10-20 02:32:41
Wave Life Sciences announced that its RNA editing therapeutic, WVE-006, successfully restored therapeutically relevant levels of the AAT enzyme in patients with Alpha-1 antitrypsin deficiency (AATD) during its phase 1b/2a trial. Despite this clinical success, Wave's stock declined by 18.6%, while rival Beam Therapeutics saw a stock increase. Analysts suggest investor expectations for higher AAT levels may have contributed to Wave's stock drop, despite the results meeting clinical significance.
2025-10-18 14:28:35
Clear Street recently initiated coverage of Wave Life Sciences (WVE), highlighting its genetic medicine pipeline, particularly WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency. This follows positive Phase 1b/2a data for WVE-006, which therapeutically restored serum AAT protein production. The article explores how renewed analyst attention and clinical trial results might influence the company's investment narrative, emphasizing that key upcoming pivotal data for WVE-006 and WVE-007 and addressing declining collaboration revenue remain critical for its future.
2025-10-15 12:07:00
Clear Street initiated coverage on WAVE Life Sciences (WVE) with a 'Buy' rating and a price target of USD 22.00, announced on October 15, 2025. This positive outlook follows several other analyst ratings, including a maintained 'Buy' from HC Wainwright & Co. and an 'Outperform' from Oppenheimer. Based on analyst forecasts, the average target price for WVE is $19.64, implying a significant upside from its current price.
2025-10-15 00:12:27
An application error occurred while loading the article content from au.investing.com, preventing the extraction of details regarding Clear Street's Buy rating for Wave Life Sciences. The article is currently unavailable due to a client-side exception.
2025-10-14 21:53:51
This article indicates that Clear Street has initiated coverage on Wave Life Sciences stock with a Buy rating. The positive rating is attributed to the potential of the company's pipeline.
2025-10-14 21:14:00
This article reports that Clear Street has initiated coverage on Wave Life Sciences stock with a "Buy" rating. The positive outlook is attributed to the potential of Wave Life Sciences' pipeline.
